Kenichi Nakamura - Concepedia

Author

Kenichi Nakamura

Also Known As

, Haruhiko Fukuda, J. K. R. Chun, K Nakamura, K. NAKAMURA, K. Nakamura, K., Nakamura, KEN-ICHI NAKAMURA, KENICHI NAKAMURA, Ken-Ichi Nakamura

423

Publications

8.8K

Citations

H-Index

169

Concepts

All Affiliations

Kumamoto University Japanese Foundation For Cancer Research National Cancer Center Hospital East Shizuoka Cancer Center Kanagawa Prefectural Hospital Organization

About

Kenichi Nakamura is an author at Kumamoto University specializing in medicine, oncology, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	78	4.8K
2	Health Sciences	11	17	1.2K
3	Public Health	4	4	175
4	Engineering	2	2	59
5	Natural Sciences	2	2	51

Kenichi Nakamura

132

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial Kazumasa Fujitani, Han‐Kwang Yang, Junki Mizusawa, The Lancet Oncology Single Non-curable FactorSurgical OncologyGastrointestinal OncologyAdvanced Gastric CancerMedicine	2016	688
A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-sized Peripheral Non-small Cell Lung Cancer (JCOG0802/WJOG4607L) Kenichi Nakamura, Hisashi Saji, R. Nakajima, Japanese Journal of Clinical Oncology	2009	525
Human Microbiome <i>Fusobacterium Nucleatum</i> in Esophageal Cancer Tissue Is Associated with Prognosis Kensuke Yamamura, Yoshifumi Baba, Shigeki Nakagawa, Clinical Cancer Research	2016	440
Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection Daisuke Kuroda, Hiroshi Sawayama, Junji Kurashige, Gastric Cancer NutritionSurgical OncologyBody CompositionGastrointestinal OncologyMedicine	2017	344
Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study) Kenichi Nakamura, Ken Kato, Hiroyasu Igaki, Japanese Journal of Clinical Oncology Surgical OncologyEsophageal CancerGastroenterologySurgeryOncology	2013	296
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Nature Medicine Tumor BiologyOncologyEsophageal CancerGastrointestinal OncologyMedicine	2018	268
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602 Takashi Onda, Toyomi Satoh, Toshiaki Saito, European Journal of Cancer Gynecologic SurgerySurgical OncologyTreatment InvasivenessNeoadjuvant ChemotherapyGynecological Surgery	2016	246
Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer Kozo Kataoka, Hiroya Takeuchi, Junki Mizusawa, Annals of Surgery	2016	212
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Journal of Clinical Oncology Surgical OncologyEsophageal CancerCancer ManagementNeoadjuvant TreatmentSurgery	2022	191
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Gastric Cancer Surgical OncologyGastrointestinal OncologyLarge Type 3MedicineGastroenterology	2020	165

Page 1